Neurology/psychiatricLEI-101 alleviates pain in preclinical modelsThe cannabinoid CB2 receptor has gained interest as a target for pain management due to its minimal involvement in central psychoactive effects compared to the CB1 receptor. LEI-101, a CB2 receptor agonist was tested in different rodent models of pain including osteoarthritis and neuropathic pain.